Product
GMCN-508A
1 clinical trial
1 indication
Indication
Transfusion-dependent Alpha-ThalassemiaClinical trial
A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With Transfusion-dependent α-Thalassemia by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral Vector (GMCN-508A Drug Product)Status: Recruiting, Estimated PCD: 2028-08-01